Fig. 2: FDI-6 and Olaparib synergistically inhibit the growth of TNBC cells in vitro. | Cell Death & Disease

Fig. 2: FDI-6 and Olaparib synergistically inhibit the growth of TNBC cells in vitro.

From: FDI-6 inhibits the expression and function of FOXM1 to sensitize BRCA-proficient triple-negative breast cancer cells to Olaparib by regulating cell cycle progression and DNA damage repair

Fig. 2

A The structure of FDI-6. B The kinase-selectivity profile of FDI-6 using an RBC kinase panel screen against 361 kinases assayed at 1.0 μM in duplicate. C IC50 values for the effects of FDI-6 and Olaparib on the viability of TNBC cells. D The effects of combining FDI-6 and Olaparib on the proliferation of TNBC cells. E CI values for concurrent treatment with FDI-6 and Olaparib in TNBC cells. The combination ratios of FDI-6/Olaparib are 1:0.25, 1:0.5, 1:1, 1:2, and 1:4. F The effects of FDI-6 and/or Olaparib on the proliferation of TNBC cells measured by colony-forming assay. The effects of FDI-6 and/or Olaparib on the apoptosis of MDA-MB-231 cells (G) and MDA-MB-468 cells (H).

Back to article page